Search

Displaying results 3201 - 3210 of 10000 in total
  1. Drug

    Trimetrexate

    go.drugbank.com/drugs/DB01157
    Approved

    A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase.

  2. Drug

    Adrafinil

    go.drugbank.com/drugs/DB08925
    ApprovedWithdrawn

    Adrafinil is metabolized to [modafinil]. … It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission.

  3. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is … [L31443,L31473] It is the first oral MET-targeted tyrosine kinase inhibitor to allow for once-daily dosing,[L31473] an advantage that may aid in easing the pill burden often associated with chemotherapeutic

  4. Drug

    Cenobamate

    go.drugbank.com/drugs/DB06119
    ApprovedInvestigational

    [A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA<sub>A</sub> and inhibits voltage gated sodium channels. … Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.

  5. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow. … Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2)

  6. Drug

    Acenocoumarol

    go.drugbank.com/drugs/DB01418
    ApprovedInvestigational

    Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation. … [A188739] Hematocrit, hemoglobin, international normalized ratio and liver panel should be monitored. Patients on acenocoumarol are prohibited from giving blood.

  7. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections … This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia [L5737].

  8. Drug

    Gemfibrozil

    go.drugbank.com/drugs/DB01241
    ApprovedInvestigational

    Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias. … [A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.

    Categories: Peroxisome Proliferator Receptor alpha Agonist, Peroxisome Proliferator-activated Receptor alpha Agonists
  9. Drug

    Torasemide

    go.drugbank.com/drugs/DB00214
    ApprovedInvestigational

    [A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]

    Products: SUTRILNEO 5 MG COMPRIMIDOS DE LIBERACIÓN PROLONGADA, SUTRILNEO 10 MG COMPRIMIDOS DE LIBERACION PROLONGADA
  10. Drug

    Cisplatin

    go.drugbank.com/drugs/DB00515
    ApprovedInvestigational

    It was the first member of its class, which now also includes carboplatin and oxaliplatin. … Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung